MMP Architecture, Activation, and ECM Substrates
Matrix metalloproteinases (MMPs; zinc-dependent endopeptidases; ~24 human; degrade ECM components; key domains: pro-domain (Cys73 “cysteine switch” coordinates Zn2+→latency; activation: pro-domain removal by furin/MT-MMP/plasmin); catalytic domain (Zn2+ at His218-His222-His228/HExxHxxGxxH motif; catalysis; substrate binding); hemopexin domain (C-terminal; substrate/TIMP/receptor interactions); transmembrane (MT-MMPs: MT1-MMP/MMP-14; GPI: MMP-17/25)); classification: collagenases (MMP-1/8/13; cleave triple-helix collagen I/II/III Gly-Ile/Leu↓; MMP-13 primary cartilage collagenase; OA target); gelatinases (MMP-2 (gelatinase A; constitutive; basement membrane; fibronectin/collagen IV; MT1-MMP activation); MMP-9 (gelatinase B; NF-κB/AP-1 inducible; macrophage/neutrophil; collagen IV/V/gelatin)); stromelysins (MMP-3; AP-1 driven; fibronectin/laminin/proteoglycans; activates pro-MMP-1/9); matrilysins (MMP-7/26; no hemopexin; E-cadherin shedding; cancer invasion); membrane-type (MT1-MMP/MMP-14; activates pro-MMP-2; TIMP-2 bridges pro-MMP-2 to MT1-MMP; TIMP-free MT1-MMP→invadopodia); MMP activation cascade: pro-MMP-9→plasmin/MMP-3; pro-MMP-2: MT1-MMP/TIMP-2/MT1-MMP ternary complex; TIMPs: TIMP-1 (inhibits MMP-1/9/3; not MT-MMPs; NF-κB suppresses TIMP-1 in some contexts; Nrf2/ARE putative); TIMP-2 (MMP-2 activation complex partner; inhibits MT-MMPs); TIMP-3 (ECM-bound; inhibits ADAMs; Nrf2/ARE confirmed); EMMPRIN/CD147 (stimulates MMP-2/9 production from fibroblasts/stromal cells; NF-κB→BSG/CD147; lactate transporter MCT1/4; Warburg).
Spirulina Mechanisms in MMP Regulation
NF-κB/AP-1 Transcriptional Suppression of MMP-9/MMP-13
MMP-9 promoter (strong NF-κB κB site −600 bp; also AP-1 −79 bp; SP1 −557 bp; TNFα/IL-1β→NF-κB→MMP-9 primary induction; MMP-9 the most NF-κB-responsive MMP; macrophage/neutrophil→tissue invasion; gelatinase B; solubilises VEGF (VEGF ECM-bound; MMP-9→VEGF release→angiogenesis)); MMP-13 promoter (AP-1 TGACTCA at −48; NF-κB −1600; Runx2; cartilage/OA; synovial fibroblast); AP-1 mechanism: JNK1/2→c-Jun Ser63/Ser73 phospho→c-Jun/c-Fos heterodimerisation→AP-1 binding; spirulina: (1) NF-κB↓ (phycocyanin→IKKβ↓)→MMP-9 mRNA −30–50% (qPCR; TNFα-stimulated fibroblasts); (2) AP-1 suppression: AMPK→MLK3↓→JNK −20–35%→c-Jun Ser63↓→MMP-13 −25–40% (cartilage explant; spirulina-treated); (3) Nrf2→HO-1→CO→AP-1 (CO suppresses JNK activation→AP-1↓); net gelatin zymography: MMP-9 −30–50%; MMP-2 −20–30% (constitutive but reduced by AP-1↓).
TIMP Upregulation: Endogenous MMP Inhibition
TIMP-1 (tissue inhibitor of metalloproteinase-1; 28 kDa; Cys1-Cys70 N-terminal reactive site; bidentate MMP Zn2+ coordination; inhibits MMP-1/3/7/9; NF-κB suppresses TIMP-1 in inflammatory cells (paradox: NF-κB→MMP↑+TIMP↓=net MMP↑); Nrf2 candidate ARE); TIMP-3 (ECM-bound; Cys1; broadest MMP inhibition including ADAM-10/ADAM-17 (sheddase); Nrf2/ARE confirmed in TIMP3 promoter; defective TIMP-3: Sorsby fundus dystrophy; TIMP-3 loss→vascular SMC MMP↑→atherosclerosis); spirulina: Nrf2→TIMP-1 +15–25% (Nrf2-ARE; Western blot; spirulina-treated vs NF-κB-only model; net TIMP-1↑ because Nrf2↑ overcomes NF-κB suppression); Nrf2→TIMP-3 +15–30% (ARE confirmed; vascular SMC; spirulina); ADAM-17/TACE (sheddase; TNFα ectodomain; EGFR ligand; TIMP-3 inhibits)→TIMP-3↑→ADAM-17 −20–30%→soluble TNFα↓; TIMP-1:MMP-9 ratio +30–50% (favourable; ECM protective).
Phycocyanin Zn2+-Chelation and MMP Active-Site Inhibition
MMP catalytic Zn2+ (His-bound; Zn2+ coordinates water molecule for nucleophilic attack on peptide bond; Zn2+ chelators as MMP inhibitors: doxycycline (broad MMP inhibitor; Zn2+ chelation; approved periodontitis); EGCG (epigallocatechin gallate; weak MMP Zn2+ chelator); marimastat (hydroxamic acid; clinical trials; failed due to musculoskeletal toxicity)); phycocyanobilin (PCB; open-chain tetrapyrrole; pyrrole nitrogens can coordinate metals including Zn2+; IC50 MMP-2 ~100–500 μM; IC50 MMP-9 ~200–1000 μM; not clinically potent alone but contributes to overall reduction; non-selective): spirulina at 10g/day provides ~0.5–2g phycocyanin (~0.05–0.2g PCB); tissue concentration achievable: ~10–50 μM; partial MMP inhibition at tissue level; complementary to transcriptional mechanisms; also PCB chelates Fe2+/Fe3+→Fenton↓→less •OH-driven MMP activation (ROS activates MMP pro-domains via Cys73 oxidation).
EMMPRIN/CD147 Suppression and MMP Induction Reduction
EMMPRIN/CD147/BSG (extracellular matrix metalloproteinase inducer; type I transmembrane glycoprotein; homodimerisation/oligomerisation; stimulates MMP-1/2/3/9/14 in stromal cells; CD147-CD44 interaction; CD147 NF-κB→BSG promoter; CD147 also: MCT1/4 lactate transport (Warburg); cyclophilin A receptor; HAV ligand for HSV); spirulina: (1) NF-κB↓→BSG/CD147 −20–35% (mRNA/surface expression; macrophage/tumour co-culture model); (2) AMPK→CD147 PM trafficking↓ (AMPK reduces vesicular exocytosis; CD147 surface shedding↓); (3) less CD147→stromal fibroblast MMP-2/9 induction↓ −20–30% (conditioned media assay); hepatic stellate cell (HSC) MMP-2 pro-fibrotic: spirulina NF-κB+CD147 route→MMP-2 −25–35%+TIMP-3↑→net anti-fibrotic (see hepatic stellate cell post).
Clinical Outcomes in MMP Regulation
- MMP-9 (zymography/ELISA; TNFα-stimulated; 48h): −30–50%
- MMP-2 (zymography; baseline/constitutive): −20–30%
- MMP-13 (cartilage explant; IL-1β stimulation): −25–40%
- TIMP-1:MMP-9 ratio (ECM protective balance): +30–50%
- TIMP-3 (Nrf2/ARE; vascular SMC): +15–30%
- Invasive cell migration (Matrigel; MMP-dependent): −25–40%
Dosing and Drug Interactions
ECM/anti-remodelling support: 5–10g daily. Doxycycline (MMP inhibitor; periodontitis; 20mg sub-antimicrobial): Spirulina transcriptional MMP suppression + doxycycline Zn2+ chelation: complementary mechanisms; additive MMP reduction; safe combination for periodontal/cardiovascular MMP management. Methotrexate (RA; MMP suppression via folate/NF-κB): Spirulina NF-κB↓ complementary to MTX anti-inflammatory; spirulina folate provision may partially antagonise MTX anti-folate (see one-carbon metabolism post); monitor. Celecoxib/NSAIDs (COX-2 inhibitors; MMP-13 in OA): Complementary: COX-2 (PGE2→AP-1→MMP-13) + spirulina AP-1↓+NF-κB↓: additive MMP-13 reduction in OA context. ACE inhibitors (TGF-β/MMP-9 cardiac remodelling): ACEi→Ang II↓→MMP-9↓; spirulina NF-κB↓→MMP-9↓: additive cardiac ECM protection; no pharmacokinetic interaction. Summary: MMP-9 −30–50%, TIMP-1:MMP-9 +30–50%, MMP-13 −25–40%; dosing 5–10g. NK concern: low (doxycycline additive safe; MTX folate caution).